• Consolidation and cost reductions securing net savings of A$1.6 million p.a.
• Acceleration of revenue generation through clearer value proposition and more commercial relationship management
• Opportunity pipeline expansion focused on commercialisation of existing products, accessing new markets, and shifting from bespoke R&D

AnteoTech Ltd has announced the outcomes of its recently completed Strategic Review, which focused on four key areas: strategic direction and priorities, cost reductions and continuous improvement, strategic partnerships, and risk management and governance. The review assessed the strategic direction, target markets, and revenue growth opportunities for both the Advanced Battery Technologies (ABT) and Life Sciences (LS) divisions. Key outcomes include consolidation and cost reductions securing net savings of A$1.6 million per annum, acceleration of revenue generation through clearer value proposition definition and more commercial relationship management, and opportunity pipeline expansion focused on commercialisation of the company's existing products, accessing new rapidly growing as well as existing markets, and shifting from bespoke R&D. The company is implementing initiatives to expand sales and marketing efforts across diverse, fast-growing markets for both ABT and LS divisions, including developing strategic partnerships and adding new sales, marketing, and commercial skills. The strategic review forms the foundation for the detailed business planning and budgeting process, with a continuous improvement approach to guide the implementation and delivery phase.

The company is targeting a 20% reduction in corporate and administration expenses for FY2026 relative to the current financial year. No other high-importance, price-sensitive forward-looking financial metrics were provided.

AnteoTech is implementing initiatives to accelerate the speed at which it converts its pipeline of opportunities to revenues by focusing on more standardised product offerings. The company is continuing to improve operations while significantly expanding its opportunity pipeline of engaged leads across both Life Sciences and Advanced Battery Technologies divisions.